Comparative Pharmacology
Head-to-head clinical analysis: OCUFEN versus OMIDRIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OCUFEN versus OMIDRIA.
OCUFEN vs OMIDRIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation and pain.
OMIDRIA is a fixed-dose combination of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist that causes vasoconstriction.
1 drop of 0.03% solution in the affected eye(s) four times daily beginning 24 hours after cataract surgery.
1 mL of the fixed-dose combination (ketorolac 0.45% / phenylephrine 1%) administered intracamerally as a single dose at the time of cataract surgery.
None Documented
None Documented
1.2 to 2.0 hours (topical administration in ocular tissues); systemic half-life is 1.1 to 1.4 hours.
Ketorolac: terminal half-life of 5.3 hours (range 3.8-8.2 hours) in adults; phenylephrine: terminal half-life of 2-3 hours. Clinically, ketorolac's half-life supports twice-daily dosing.
Urinary excretion of unchanged drug accounts for approximately 82% of a topical dose; fecal excretion is minor (<5%).
Renal elimination of ketorolac accounts for approximately 91% of the dose, with approximately 60% as unchanged drug and the remainder as metabolites; phenylephrine is primarily metabolized and excreted in urine as sulfate conjugates, with <20% excreted unchanged.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID and Mydriatic Combination